Estrogenic compounds may influence the growth, differentiation and function in many target tissues, especially in the female reproductive tract during pregnancy. The present study was designed to investigate whether CaBP-9k expression in the maternal tissues and fetal uterus is altered following maternal treatment with diethylstilbestrol (DES), 17beta-estradiol (E2), 4-tert-octylphenol (OP), nonylphenol (NP) and bisphenol A (BPA) during late pregnancy. The expression level of CaBP-9k mRNA in maternal uterus significantly increased when treated with a high dose (600 mg/kg BW per day) of OP and NP. Interestingly, the expression level of CaBP-9k mRNA in extra-embryonic membrane decreased in a dose-dependent manner, suggesting that the expression level of CaBP-9k mRNA in the fetal membrane may be differentially regulated when compared to the expression of CaBP-9k in maternal uterus. In parallel with CaBP-9k mRNA level, a high dose (600 mg/kg) of OP and BPA resulted in an increase of CaBP-9k protein in maternal uterus and low dose of OP and NP increased the expression level of CaBP-9k protein in the placenta. High doses of BPA (400 and 600 mg/kg) resulted in an increase of CaBP-9k protein in maternal uterus and placenta, indicating that these estrogenic compounds may affect both maternal uterus and placenta in the induction of CaBP-9k mRNA and/or protein. In parallel with the expression level of CaBP-9k, mRNA decreased in extra-embryonic membrane, treatment with OP (400 and 600 mg/kg) resulted in a significant decrease of CaBP-9k protein in this tissue, suggesting that both CaBP-9k mRNA and protein may be conversely regulated by OP in extra-embryonic membrane when compared to other tissues. Treatment with OP, NP, and BPA induced a significant increase of CaBP-9k mRNA in fetal uterus, indicating that maternally injected estrogenic compounds may transfer directly from placenta to fetus in the induction of fetal uterus CaBP-9k gene. Taken together, we demonstrated for the first time that maternally injected estrogenic compounds resulted in an increase of CaBP-9k mRNA and/or protein in the maternal tissues (uterus and placenta) and fetal uterus during late pregnancy, suggesting that placenta may not be a reliable barrier against these estrogenic compounds for fetal health.